statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D...

Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release...

Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024

Marinus Pharmaceuticals provides updates on Phase 3 RAISE trial for refractory status epilepticus treatment with IV ganaxolone. With enrollment completion expected, topline results are anticipated by...

Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday?

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data...

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement...

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Investors considering a purchase of Marinus Pharmaceuticals Inc (MRNS) stock, but tentative about paying the going market price of 8.95/share, might benefit from considering selling puts among...

Commit To Buy Marinus Pharmaceuticals At $7, Earn 104.8% Annualized Using Options

This indicator may be signaling that MRNS's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Marinus Pharmaceuticals (MRNS, $8.98) entered Downtrend as Momentum indicator drops below 0 level on Apr 01, 2024

This is a Bullish indicator signaling MRNS's price could rise from here. Traders may explore going long the stock or buying call options...

Marinus Pharmaceuticals (MRNS, $9.04) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 28, 2024

As a company grounded in scientific research, we will vigorously defend our patents, said Marinus CEO Dr. Scott Braunstein...

Marinus Pharmaceuticals' patent battle with New York firm over seizure therapy takes new twist

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to...

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus Post Grant Review

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded in August 2003 and is headquartered in Radnor, PA.

Volume	3,008.00
52-Wk High	$11.26
52-Wk Low	$1.11

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.66	--	--	N/A
Q4'23	-$0.62	-$0.74	-18.74%	MISSED
Q3'23	-$0.66	-$0.61	7.70%	BEAT
Q2'23	-$0.73	-$0.61	15.98%	BEAT
Q1'23	-$0.73	-$0.67	8.36%	BEAT

MRNS Marinus Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals